סיטאר 25 - Sitar 25
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |
|---|---|
| ×§×××¦× ×¤×¨××§×××××ת (ATC4) | A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors |
| ×ר××× ×¤×¢×× (ATC5) | Â
|
| צ×רת ××ª× | פ××× - PER OS |
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× |
| ×ת×××× | SITAR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: SITAR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. SITAR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using SITAR. |
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
  |
| ×¢××× ×צר×× |  |
|---|
| ער××× ×××××§×רפ××× | ער××× ×§×©×ר×× ×××××§×רפ××× |
|---|---|
| ס×××ר 25 ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | LABORATORIOS LICONSA S.A., SPAIN |
| ×©× ××¢× ×ר×ש×× | UNIPHARM TRADING LTD, ISRAEL |
| ר×ש××× | ת×ר×× ××ש×: 7/2020. ר×ש××× ×ת×ר××: |
| ת×ר×× ×¢×××× ××ר×× | 26/06/2024 |
השינוי האחרון נעשה בֹ־26 ביוני 2024 ב־14:55